Search

Your search keyword '"JUNG G"' showing total 41 results

Search Constraints

Start Over You searched for: Author "JUNG G" Remove constraint Author: "JUNG G" Topic liver neoplasms Remove constraint Topic: liver neoplasms
41 results on '"JUNG G"'

Search Results

1. RNA sequencing analysis of hepatocellular carcinoma identified oxidative phosphorylation as a major pathologic feature.

2. SERPINA3 is a key modulator of HNRNP-K transcriptional activity against oxidative stress in HCC.

3. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.

4. Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors.

5. Oxidatively Modified Protein-Disulfide Isomerase-Associated 3 Promotes Dyskerin Pseudouridine Synthase 1-Mediated Malignancy and Survival of Hepatocellular Carcinoma Cells.

6. Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma.

7. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.

9. Reactive oxygen species increase HEPN1 expression via activation of the XBP1 transcription factor.

10. Notch1 increases Snail expression under high reactive oxygen species conditions in hepatocellular carcinoma cells.

11. Positive association of long telomeres with the invasive capacity of hepatocellular carcinoma cells.

12. Co-expression patterns of Notch1, Snail, and p53 in grade III hepatocellular carcinoma with postoperative recurrence: a preliminary study.

13. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival.

14. Notch1 binds and induces degradation of Snail in hepatocellular carcinoma.

15. Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.

16. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.

17. Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma.

18. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma.

19. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation?

20. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis.

21. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.

22. [Model for end-stage liver disease. New basis of allocation for liver transplantations].

23. Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation.

24. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial.

25. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA.

26. [Differential diagnosis of focal liver lesions using contrast-enhanced MRI with SHU 555 A in comparison with unenhanced MRI and multidetector spiral-CT].

27. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase.

28. Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway.

30. [Contrast-enhanced sonography using Levovist is decisive for staging and therapeutic schedule in hepatocellular carcinoma].

31. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma.

32. CT and MRI findings of multifocal hepatic steatosis mimicking malignancy.

33. Proteome analysis of hepatocellular carcinoma.

34. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool.

35. Liver transplantation for hepatoblastoma in the pediatric population.

36. Detection of focal hepatic lesions: effects of superparamagnetic iron oxide (AMI-25) on magnetic resonance imaging of the liver using T2-weighted fast spin-echo sequences and gradient-and-spin-echo sequences at 1.0 tesla.

37. Prospective comparison of fast SE and GRASE sequences and echo planar imaging with conventional SE sequences in the detection of focal liver lesions at 1.0 T.

38. Late results after resection of benign hepatic tumors: clinical and radiological findings.

39. Delineation of segmental liver anatomy. Comparison of ultrasonography, spiral CT and MR imaging for preoperative localization of focal liver lesions to specific hepatic segments.

40. [Comparison of fast turbo-spin-echo and gradient- and spin-echo sequences as well as echo planar imaging with conventional spin-echo sequences in MRI of focal liver lesions at 1.0 tesla].

41. [Comparison of fast turbo-spin-echo and gradient- and spin-echo sequences as well as echo planar imaging with conventional spin-echo sequences in MRI of focal liver lesions at 1.0 tesla]

Catalog

Books, media, physical & digital resources